Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol

The combination drug "polymyxin B sulphate + prednisolone + benzocaine + clioquinol" is a topical medication used primarily for treating acute and sub-acute dermatitis eczematous conditions. This combination provides multiple therapeutic effects through its components. ## Composition and Mechanism This medication combines four active ingredients, each serving a specific purpose: 1. **Polymyxin B Sulphate**: An antibiotic component that disrupts the outer cell membrane of Gram-negative bacteria. It binds to and neutralizes lipopolysaccharide (LPS) and inhibits bacterial respiration[7][9]. It's particularly effective against Pseudomonas aeruginosa and other Gram-negative pathogens[6][7]. 2. **Prednisolone**: A glucocorticoid with anti-inflammatory properties that helps reduce inflammation, swelling, and redness associated with dermatitis[5][8]. 3. **Benzocaine**: A topical local anesthetic that provides temporary pain relief and reduces itching in affected areas[10]. 4. **Clioquinol**: An antimicrobial agent with both antibacterial and antifungal properties, enhancing the broad-spectrum activity of the combination[3]. ## Clinical Applications The combination has been specifically studied for effectiveness in acute and sub-acute dermatitis eczematous conditions. A clinical trial (NCT01429701) evaluated this combination through a double-blinded, non-inferiority, prospective parallel-group study[2][4]. The trial design included: - 22-day experiment duration - Multiple evaluation visits (days 0, 7, 15, and 22) - Assessment using the eczema area and severity index - Monitoring of adverse events[2][4] ## Effectiveness The combination appears to be effective in treating dermatitis, with clinical trials showing positive results. The synergistic effects between the components enhance the overall efficacy of the medication. For example, similar combinations like polymyxin B with miconazole and prednisolone have demonstrated synergistic antimicrobial effects in veterinary applications[5][8]. ## Safety Considerations The medication should be used with caution in certain populations. The clinical trial excluded: - Pregnant women or those at risk of pregnancy - Lactating women - Patients using anti-inflammatory or immunosuppressive drugs within 30 days prior to treatment - Those with excessive sunlight exposure in the previous 15 days - Patients with pathologies that might interfere with the protocol[2][4] This combination medication represents a multi-modal approach to treating dermatitis, addressing infection, inflammation, and discomfort simultaneously through its four active components.